Development of folate-appended cyclodextrin as a tumor-selective drug carrier

2015 Fiscal Year Final Research Report

• Project/Area Number: 25870537
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Physical pharmacy; Medical pharmacy
• Research Institution: Kumamoto University
• Principal Investigator: MOTOYAMA KEIICHI 熊本大学, 大学院生命科学研究部, 准教授 (50515608)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: シクロデキストリン / 抗がん剤 / ドラッグデリバリーシステム

Outline of Final Research Achievements

In the present study, to make an attempt to confer a tumor cell-selectivity to M-β-CyD, we newly synthesized folate-appended M-β-CyD (FA1-M-β-CyD), and evaluated the potentials as its novel tumor-selective carrier for antitumor drugs. FA1-M-β-CyD showed potent antitumoreffects in FR-expressing tumor cells in vitro and in vivo. Furthermore, Doxorubicin/FA1-M-β-CyD complex showed the potent antitumor activity after single intravenous injection to tumor-bearing mice, compared to doxorubicin alone and DOX/M-β-CyD complex. In conclusion, the present study demonstrated the potentials of FA1-M-β-CyD as a novel tumor-selective carrier for antitumor drugs.

Free Research Field

医歯薬学